MicroRNA-mediated control of myocardial infarction in diabetes

Trends Cardiovasc Med. 2023 May;33(4):195-201. doi: 10.1016/j.tcm.2022.01.004. Epub 2022 Jan 17.

Abstract

Diabetes mellitus is a global public health problem whose cases will continue to rise along with the progressive increase in obesity and the aging of the population. People with diabetes exhibit higher risk of cardiovascular complications, especially myocardial infarction (MI). microRNAs (miRNAs) are evolutionary conserved small non-coding RNAs involved in the regulation of biological processes by interfering in gene expression at the post-transcriptional level. Accumulating studies in the last two decades have uncovered the role of stage-specific miRNAs associated with key pathobiological events observed in the hearts of people with diabetes and MI, including cardiomyocyte death, angiogenesis, inflammatory response, myocardial remodeling, and myocardial lipotoxicity. A better understanding of the importance of these miRNAs and their targets may provide novel opportunities for RNA-based therapeutic interventions to address the increased risk of MI in diabetes.

Keywords: Diabetes; Myocardial infarction; microRNA.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus* / diagnosis
  • Diabetes Mellitus* / genetics
  • Diabetes Mellitus* / therapy
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Myocardial Infarction* / genetics
  • Myocardial Infarction* / metabolism
  • Myocardial Infarction* / prevention & control
  • Myocardium / metabolism
  • Myocytes, Cardiac / metabolism

Substances

  • MicroRNAs